| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Ivonescimab Basic information |
| Product Name: | Ivonescimab | | Synonyms: | Ivonescimab;Research Grade Ivonescimab (DHD12605);Research Grade Ivonescimab;AK112 | | CAS: | 2428381-53-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ivonescimab Structure]() |
| | Ivonescimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Ivonescimab Usage And Synthesis |
| Uses | Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research[1][2][3]. | | References | [1] Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9:
[2] Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10:
[3] Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517. |
| | Ivonescimab Preparation Products And Raw materials |
|